Erleada and Theraflu Warming Severe Cold Daytime

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.MONITOR: Coadministration with apalutamide may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4, 2C9, 2C19, breast cancer resistance protein (BCRP), uridine diphosphate glucuronosyltransferase (UGT), organic anion transporting polypeptide 1B1 (OATP1B1), and/or P-glycoprotein (P-gp) efflux transporter. The proposed mechanism involves accelerated clearance via these routes due to apalutamide-mediated induction. The resulting plasma concentrations will depend on the sensitivity of the affected drugs to these isoenzymes. MANAGEMENT: Caution is advised when apalutamide is used concomitantly with drugs that are substrates of CYP450 3A4, 2C9, 2C19, BCRP, UGT, OATP1B1, and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever apalutamide is added to or withdrawn from therapy. References "Product Information. Erleada (apalutamide)." Janssen Biotech, Inc., Horsham, PA, PA. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

MONITOR: Coadministration with apalutamide may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4, 2C9, 2C19, breast cancer resistance protein (BCRP), uridine diphosphate glucuronosyltransferase (UGT), organic anion transporting polypeptide 1B1 (OATP1B1), and/or P-glycoprotein (P-gp) efflux transporter. The proposed mechanism involves accelerated clearance via these routes due to apalutamide-mediated induction. The resulting plasma concentrations will depend on the sensitivity of the affected drugs to these isoenzymes.

MANAGEMENT: Caution is advised when apalutamide is used concomitantly with drugs that are substrates of CYP450 3A4, 2C9, 2C19, BCRP, UGT, OATP1B1, and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever apalutamide is added to or withdrawn from therapy.

Erleada

Generic Name: apalutamide

Brand name: Erleada

Synonyms: n.a.

What is Erleada?

Theraflu Warming Severe Cold Daytime

Generic Name: acetaminophen / dextromethorphan / phenylephrine

Brand name: Comtrex Cold & Cough, DayQuil Cold & Flu, Daytime, Flu & Severe Cold & Cough Daytime Powder, Mapap Cold Formula, Robitussin Peak Cold Daytime Cold + Flu, Sudafed PE Pressure+Pain+Cough, Theraflu Daytime Severe Cold & Cough, Theraflu Warming Severe Cold Daytime, Tylenol Cold Multi-Symptom Daytime, Vicks Dayquil Liquicaps Cold/Flu, Contac Complete Cough, Cold & Flu Extra Strength, Tylenol Cold Daytime, Neocitran Non Drowsy Extra Strength Cold and Flu, Tylenol Cold Daytime Extra Strength, Tylenol Flu Daytime Extra Strength, Theraflu Nighttime Severe Cold & Cough, Theraflu Warming Relief Daytime Multi-Symptom Cold, Tylenol Children's Plus Cold & Cough, Theraflu Multi-Symptom Severe Cold, Day Time Cold & Flu, DayQuil Nature Fusion Cold & Flu, Theraflu ExpressMax Day Cold & Cough, Tylenol Cold Max Day, Mucinex Fast-Max Severe Cold and Sinus, Mucinex Fast-Max Congestion and Headache, Theraflu PowerPods Daytime Severe Cold, Comtrex Cold and Cough Maximum Strength, Vicks DayQuil Multi-Symptom Cold/Flu Relief

Synonyms: n.a.

What is Theraflu Warming Severe Cold Daytime?